The role of E3 ubiquitin ligase Cbl proteins in β-Elemene reversing multi-drug resistance of human gastric adenocarcinoma cells

International Journal of Molecular Sciences

Volumn 14, Issue 5, 2013, Pages 10075-10089

  Zhang, Ye ^a   Mu, Xiao Dong ^a   Li, En Zhe ^a   Luo, Ying ^a   Song, Na ^a   Qu, Xiu Juan ^a   Hu, Xue Jun ^a   Liu, Yun Peng ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

and beta; elemene; E3 ubiquitin ligase; Multidrug resistance; PI3K Akt

Indexed keywords

BETA ELEMENE; CBL PROTEIN; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; MULTIDRUG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHODAMINE 123; VERAPAMIL; ANTINEOPLASTIC AGENT; BETA-ELEMENE; CBLB PROTEIN, HUMAN; SESQUITERPENE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN PHOSPHORYLATION; STOMACH ADENOCARCINOMA; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CURCUMA; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NUDE MOUSE; SIGNAL TRANSDUCTION; STOMACH; STOMACH NEOPLASMS; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CURCUMA; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-CBL; SESQUITERPENES; SIGNAL TRANSDUCTION; STOMACH; STOMACH NEOPLASMS;

EID: 84877831142     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140510075     Document Type: Article

References (34)

1. Sui, H.; Fan, Z.Z.; Li, Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J. Int. Med. Res. 2012, 40, 426-435.
2. Wu, H.; Kang, H.; Liu, Y.; Tong, W.; Liu, D.; Yang, X.; Lian, M.; Yao, W.; Zhao, H.; Huang, D.; et al. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes. J. Cancer Res. Clin. Oncol. 2012, 138, 1449-1462.
3. Amiri-Kordestani, L.; Basseville, A.; Kurdziel, K.; Fojo, A.T.; Bates, S.E. Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies. Drug Resist. Updat. 2012, 15, 50-61.
4. De Moraes, A.C.; Licínio, M.A.; Zampirolo, J.A.; Liedke, S.C.; Del Moral, J.A.; Machado, M.J.; Bazzo, M.L.; da Silva, M.C. Evaluation of multidrug resistance in 46 newly diagnosed patients with acute leukemia. Hematology 2012, 17, 59-65.
5. Robey, R.W.; Massey, P.R.; Amiri-Kordestani, L.; Bates, S.E. ABC transporters: Unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med. Chem. 2010, 10, 625-633.
6. Yu, Z.; Wang, R.; Xu, L.; Xie, S.; Dong, J.; Jing, Y. β-Elemene piperazine derivatives induce apoptosis in human leukemia cells through downregulation of c-FLIP and generation of ROS. PLoS One 2011, 6, e15843.
7. Li, Q.Q.; Wang, G.; Huang, F.; Banda, M.; Reed, E. Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J. Pharm. Pharmacol. 2010, 62, 1018-1027.
8. Li, L.J.; Zhong, L.F.; Jiang, L.P.; Geng, C.Y.; Zou, L.J. β-Elemene radiosensitizes lung cancer A549 cells by enhancing DNA damage and inhibiting DNA repair. Phytother. Res. 2011, 25, 1095-1097.
9. Li, L.J.; Zhong, L.F.; Jiang, L.P.; Geng, C.Y.; Zhu, T.Z.; Xu, Y.H.; Wang, Q.; Qu, Y.; Shao, J.; Zou, L.J. Lysosomal membrane permeabilization contributes to elemene emulsion-induced apoptosis in A549 cells. Free Radic. Res. 2011, 45, 1232-1240.
10. Lee, R.X.; Li, Q.Q.; Reed, E. β-elemene effectively suppresses the growth and survival of both platinum-sensitive and-resistant ovarian tumor cells. Anticancer Res. 2012, 32, 3103-3113.
11. Zhan, Y.H.; Liu, J.; Qu, X.J.; Hou, K.Z.; Wang, K.F.; Liu, Y.P.; Wu, B. β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways. Asian Pac. J. Cancer Prev. 2012, 13, 2739-2744.
12. Chen, X.; Wang, Y.; Luo, H.; Luo, Z.; Zhang, T.; Yang, N.; Long, X.; Xie, H.; Qiu, W.; Zhang, B.; et al. β-elemene acts as an antitumor factor and downregulates the expression of survivin, Bcl-xL and Mta-1. Mol. Med. Report 2012, 6, 989-995.
13. Zhu, T.; Xu, Y.; Dong, B.; Zhang, J.; Wei, Z.; Xu, Y.; Yao, Y. β-elemene inhibits proliferation of human glioblastoma cells through the activation of glia maturation factor β and induces sensitization to cisplatin. Oncol. Rep. 2011, 26, 405-413.
14. Zhu, T.; Zhao, Y.; Zhang, J.; Li, L.; Zou, L.; Yao, Y.; Xu, Y. ß-Elemene inhibits proliferation of human glioblastoma cells and causes cell-cycle G0/G1 arrest via mutually compensatory activation of MKK3 and MKK6. Int. J. Oncol. 2011, 38, 419-426.
15. Wang, B.; Peng, X.X.; Sun, R.; Li, J.; Zhan, X.R.; Wu, L.J.; Wang, S.L.; Xie, T. Systematic review of β-elemene injection as adjunctive treatment for lung cancer. Chin. J. Integr. Med. 2012, 18, 813-823.
16. Xu, H.B.; Li, L.; Fu, J.; Mao, X.P.; Xu, L.Z. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene. Pharmacology 2012, 89, 303-312.
17. McCubrey, J.A.; Steelman, L.S.; Abrams, S.L.; Lee, J.T.; Chang, F.; Bertrand, F.E.; Navolanic, P.M.; Terrian, D.M.; Franklin, R.A.; D'Assoro, A.B.; et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 2006, 46, 249-279.
18. Zhang, Y.; Qu, X.J.; Liu, Y.P.; Yang, X.H.; Hou, K.Z.; Teng, Y.E.; Zhang, J.D. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR. Ai Zheng 2009, 28, 97-99.
19. Barancík, M.; Bohácová, V.; Sedlák, J.; Sulová, Z.; Breier, A. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 2006, 29, 426-434.
20. Steelman, L.S.; Stadelman, K.M.; Chappell, W.H.; Horn, S.; Bäsecke, J.; Cervello, M.; Nicoletti, F.; Libra, M.; Stivala, F.; Martelli, A.M.; et al. Akt as a therapeutic target in cancer. Expert Opin. Ther. Targets 2008, 12, 1139-1165.
21. Dulinska-Litewka, J.; McCubrey, J.A.; Laidler, P. Increased akt signaling resulting from the loss of androgen responsiveness in prostate cancer. Curr. Med. Chem. 2013, 20, 144-157.
22. Choi, B.H.; Kim, C.G.; Lim, Y.; Shin, S.Y.; Lee, Y.H. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008, 18, 111-118.
23. Mohapatra, B.; Ahmad, G.; Nadeau, S.; Zutshi, N.; An, W.; Scheffe, S.; Dong, L.; Feng, D.; Goetz, B.; Arya, P.; et al. Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases. Biochim. Biophys. Acta 2013, 1833, 122-139.
24. Brennan, T.; Adapala, N.S.; Barbe, M.F.; Yingling, V.; Sanjay, A. Abrogation of Cbl-PI3K interaction increases bone formation and osteoblast proliferation. Calcif. Tissue Int. 2011, 89, 396-410.
25. Adapala, N.S.; Barbe, M.F.; Langdon, W.Y.; Nakamura, M.C.; Tsygankov, A.Y.; Sanjay, A. The loss of Cbl-phosphatidylinositol 3-kinase interaction perturbs RANKL-mediated signaling, inhibiting bone resorption and promoting osteoclast survival. J. Biol. Chem. 2010, 285, 36745-36758.
26. Zhang, Y.; Qu, X.; Hu, X.; Yang, X.; Hou, K.; Teng, Y.; Zhang, J.; Sada, K.; Liu, Y. Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J. Pathol. 2009, 218, 248-255.
27. Li, Q.Q.; Lee, R.X.; Liang, H.; Zhong, Y. Anticancer Activity of β-Elemene and its synthetic analogs in human malignant brain tumor cells. Anticancer Res. 2013, 33, 65-76.
28. Li, L.; Xu, L.; Qu, X.; Zhao, M.; Yu, P.; Kang, J.; Liu, Y.; Hu, X. Cbl-regulated Akt and ERK signals are involved in β-elemene-induced cell apoptosis in lung cancer cells. Mol. Med. Report 2011, 4, 1243-1246.
29. Wang, J.W.; Zhang, H.P.; Sun, Y. Phase IlI clinical trial of elemene emulsion in the management of malignant pleural and peritoneal effusion. Chin. J. Oncol. 1996, 18, 464.
30. Tan, P.; Zhong, W.; Cai, W. Clinical study on treatment of 40 cases of malignant brain tumor by elemene emulsion injection. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000, 20, 645-648.
31. Li, Q.Q.; Lee, R.X.; Liang, H.; Zhong, Y.; Reed, E. Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells. Med. Oncol. 2013, 30, 424.
32. Zhang, F.; Xu, L.; Qu, X.; Zhao, M.; Jin, B.; Kang, J.; Liu, Y.; Hu, X. Synergistic antitumor effect of β-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. Mol. Med. Report 2011, 4, 1189-1193.
33. Lee, J.T., Jr.; Steelman, L.S.; McCubrey, J.A. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004, 64, 8397-8404.
34. Xu, L.; Zhang, Y.; Liu, J.; Qu, J.; Hu, X.; Zhang, F.; Zheng, H.; Qu, X.; Liu, Y. TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells. Eur. J. Cancer 2012, 48, 3288-3299.